KLOW takes the three peptides in the Glow blend and adds KPV, a short anti-inflammatory fragment of alpha-MSH that has been studied mostly in models of colitis. The pitch is that anti-inflammatory, tissue-repair and matrix-remodelling signals in one injection do more together than separately. That is an assertion, not a finding: there is no combination study, no stability data for four peptides in one vial, and no interaction work.
A compounded blend of KPV (Lys-Pro-Val, the C-terminal tripeptide of α-MSH, reported to inhibit NF-κB signalling and reduce inflammatory cytokine production in colitis models), GHK-Cu, BPC-157 and TB-500. Component ratios are supplier-specific and unstandardised. No pharmacokinetic, stability, compatibility or efficacy data exists for the mixture. The presence of a copper complex alongside three other peptides in solution is a formulation question that no vendor documentation addresses.